Patient No. | 1 | 2 | 3 | 4 |
---|---|---|---|---|
Age, yrs/sex | 30/F | 51/M | 49/F | 42/F |
Disease duration, yrs | 0.7 | 1.0 | 12.0 | 4.0 |
Drug treatment before secukinumab | NSAID | NSAID | TNFi, THD, SASP, and NSAID | NSAID |
Follow-up, wks | 25.1 | 25.7 | 24.6 | 24.4 |
Osteoarticular pain | ACW, spine, sacroiliac region, and shoulder | ACW, spine, sacroiliac region, shoulder, and hip | ACW, spine, and shoulder | ACW, spine, sacroiliac region, and shoulder |
Lesions revealed by whole-body bone scintigraphy |
|
|
|
|
Lesions revealed by whole-body MRI |
|
|
|
|
Rash | PPP + nail lesions | PPP + PV + nail lesions | PPP + PV + nail lesions | PPP + PV + nail lesions |
Patient-reported osteoarticular outcomes | ||||
VAS50 | Yes | No | Yes | Yes |
BASDAI50 | Yes | Yes | Yes | Yes |
ASDAS-MI | Yes | Yes | Yes | Yes |
MRI outcomes* | Complete resolution of all lesions |
|
|
|
Rash outcomes |
|
|
|
|
Adverse events |
| None | Herpes zoster |
|
↵*Complete resolution, significant remission, and partial remission were defined as disappearance, ≥ 50% remission, and < 50% remission of the lesion. ACW: anterior chest wall; ASDAS-MI: Ankylosing Spondylitis Disease Activity Score major improvement ≥ 2.0; BASDAI50: ≥ 50% improvement in Bath Ankylosing Spondylitis Disease Activity Index; MRI: magnetic resonance imaging; MTP: metatarsophalangeal joint; NSAID: nonsteroidal antiinflammatory drugs; PPP: palmoplantar pustulosis; PV: psoriasis vulgaris; SAPHO: synovitis, acne, pustulosis, hyperostosis, and osteitis; SASP: salicylazosulfapyridine; THD: thalidomide; TNFi: tumor necrosis factor inhibitor; VAS50: ≥ 50% improvement in visual analog scale.